---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-23-000020"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:11:45.621033+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Halozyme says EPO revokes Janssen co-formulation patent; reaffirms 2023 guidance

## Summary
- EPO Opposition Division revoked Janssen's European Patent EP3370770B1 for DARZALEX SC co-formulation.
- Halozyme reiterates 2023 revenue guidance of $815M-$845M and royalty revenue of $445M-$455M.
- Affirms total royalty revenue projection of ~$1B by 2027 and thereafter to at least 2030.
- License with Janssen: co-formulation patents do not extend royalty step-down beyond 2024 in EU, 2027 in US.
- Written decision expected in months; if appeal filed, patent remains in force until final decision.

## SEC filing metadata
- accession: 0001159036-23-000020
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000020/0001159036-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000020/halo-20230315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-23-000020
- JSON: https://secwatch.observer/filing/0001159036-23-000020.json
- Plain text: https://secwatch.observer/filing/0001159036-23-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.